Benzinga

Benzinga

Benzinga

miércoles, agosto 19

Indaptus Therapeutics Inc

INDPNASDAQ
Trade with Public
Trade with Public
$0.9361
-0.0639-6.39%
al cierre: Aug 17, 5:00 PM EST
$0.9374
-0.0626-6.26%
Premercado: 4:14 AM EST
Ganancias: Los beneficios de Q2 2026 se publicaron el jue ago 13th, antes de la apertura del mercado
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararInforme de acciones

Indaptus Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Indaptus Therapeutics (INDP).

Price Target Range — 3 Quarters

Analyst Consensus — 2 Analysts

2Buy
Consensus RatingBuy# Analysts2Avg. Consensus PT$9Upside to Avg. PT+806.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Nov 13, 2024Maxim GroupJason McCarthyPT CutBuy$8→$5
Oct 16, 2024HC Wainwright & Co.Raghuram SelvarajuMaintainedBuy$12
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Maxim Group Maintains Buy on Indaptus Therapeutics, Lowers Price Target to $5

Maxim Group analyst Jason McCarthy maintains Indaptus Therapeutics (NASDAQ:INDP) with a Buy and lowers the price target from $8 to $5.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Indaptus Therapeutics (NASDAQ:INDP) with a Buy and maintains $12 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Indaptus Therapeutics (NASDAQ:INDP) with a Buy and maintains $12 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Indaptus Therapeutics (NASDAQ:INDP) with a Buy and maintains $12 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Indaptus Therapeutics (NASDAQ:INDP) with a Buy and maintains $12 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Indaptus Therapeutics (NASDAQ:INDP) with a Buy and maintains $12 price target.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved